Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea.
Department of Biostatistics, Korea University College of Medicine, Seoul, Republic of Korea.
Diab Vasc Dis Res. 2019 Nov;16(6):530-538. doi: 10.1177/1479164119860746. Epub 2019 Jul 8.
A recent experimental study revealed that family with sequence similarity 19 [chemokine (C-C motif)-like] member A5 (FAM19A5), a novel secreted adipokine, has inhibitory effects on vascular smooth muscle cell proliferation and migration, and on neointima formation in injured arteries. We investigated the associations between serum FAM19A5 concentration and cardio-metabolic risk factors for the first time in human subjects.
Circulating FAM19A5 concentrations and their associations with cardio-metabolic risk factors were explored in 223 individuals (45 without diabetes and 178 with type 2 diabetes).
Serum FAM19A5 concentrations (pg/mL) were greater in patients with type 2 diabetes [median (interquartile range), 172.70 (116.19, 286.42)] compared with non-diabetic subjects [92.09 (70.32, 147.24)] ( < 0.001). Increasing serum FAM19A5 tertile was associated with trends of increasing waist-to-hip ratio, fasting plasma glucose, glycated haemoglobin and mean brachial-ankle pulse wave velocity. Serum FAM19A5 was positively correlated with waist circumference, waist-to-hip ratio, alanine aminotransferase, fasting plasma glucose, glycated haemoglobin and mean brachial-ankle pulse wave velocity. Multiple stepwise regression analyses identified waist-to-hip ratio, low-density lipoprotein cholesterol and brachial-ankle pulse wave velocity as determining factors for log-transformed serum FAM19A5 concentration (R = 0.0689).
A novel adipokine FAM19A5 was related to various metabolic and vascular risk factors in humans, suggesting its potential as a biomarker of cardio-metabolic disease.
最近的一项实验研究表明，家族性序列相似性 19 成员 A5（趋化因子（C-C 基序）样），一种新型分泌脂肪因子，对血管平滑肌细胞增殖和迁移以及损伤动脉中的新生内膜形成具有抑制作用。我们首次在人体中研究了血清 FAM19A5 浓度与心脏代谢危险因素之间的关系。
在 223 名个体（45 名无糖尿病和 178 名 2 型糖尿病）中，研究了循环 FAM19A5 浓度及其与心脏代谢危险因素的关系。
与非糖尿病患者[中位数（四分位距），92.09（70.32，147.24）相比，2 型糖尿病患者的血清 FAM19A5 浓度（pg/ml）[中位数（四分位距），172.70（116.19，286.42）]更高（<0.001）。随着血清 FAM19A5 三分位的增加，腰围-臀围比、空腹血糖、糖化血红蛋白和平均肱踝脉搏波速度呈上升趋势。血清 FAM19A5 与腰围、腰围-臀围比、丙氨酸氨基转移酶、空腹血糖、糖化血红蛋白和平均肱踝脉搏波速度呈正相关。多元逐步回归分析确定腰围-臀围比、低密度脂蛋白胆固醇和肱踝脉搏波速度为对数转换后血清 FAM19A5 浓度的决定因素（R=0.0689）。
一种新型脂肪因子 FAM19A5 与人类的各种代谢和血管危险因素有关，表明其作为心脏代谢疾病生物标志物的潜力。
